2022. Comparative analysis of the use of technetium-99m labeled recombinant target molecules at doses of 1000 and 2000 μg for radionuclide diagnostics of HER2-positive breast cancer. Voprosy onkologii. 68, 1 (Feb. 2022), 60–65. DOI:https://doi.org/10.37469/0507-3758-2022-68-1-60-65.